Cargando…

Lubiprostone: a novel treatment for chronic constipation

Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacy, Brian E, Levy, L Campbell
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546479/
https://www.ncbi.nlm.nih.gov/pubmed/18686757
_version_ 1782159206324895744
author Lacy, Brian E
Levy, L Campbell
author_facet Lacy, Brian E
Levy, L Campbell
author_sort Lacy, Brian E
collection PubMed
description Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.
format Text
id pubmed-2546479
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-25464792009-05-20 Lubiprostone: a novel treatment for chronic constipation Lacy, Brian E Levy, L Campbell Clin Interv Aging Review Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication. Dove Medical Press 2008-06 2008-06 /pmc/articles/PMC2546479/ /pubmed/18686757 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Lacy, Brian E
Levy, L Campbell
Lubiprostone: a novel treatment for chronic constipation
title Lubiprostone: a novel treatment for chronic constipation
title_full Lubiprostone: a novel treatment for chronic constipation
title_fullStr Lubiprostone: a novel treatment for chronic constipation
title_full_unstemmed Lubiprostone: a novel treatment for chronic constipation
title_short Lubiprostone: a novel treatment for chronic constipation
title_sort lubiprostone: a novel treatment for chronic constipation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546479/
https://www.ncbi.nlm.nih.gov/pubmed/18686757
work_keys_str_mv AT lacybriane lubiprostoneanoveltreatmentforchronicconstipation
AT levylcampbell lubiprostoneanoveltreatmentforchronicconstipation